What is happening with Novavax?

What is happening with Novavax?

2022-11-22 • Updated

What is Novavax?

Novavax Inc. is an American biotechnology company that develops vaccines to fight severe infectious diseases. By 2020, company scientists have developed experimental vaccines against Ebola, influenza, respiratory syncytial virus (RSV), and other emerging infectious diseases. In 2020, the company refocused its efforts on developing and approving its NVX-CoV2373 COVID-19 vaccine. In addition, Novavax indicated that it recognizes the ongoing need for innovative vaccines in other therapeutic areas and says it has taken steps to ensure that its influenza vaccine is further improved.

Their Nuvaxovid vaccine was approved in the EU at the end of 2021 and in Canada in February 2022 as the fifth COVID-19 vaccine after Pfizer/BioNTech, Moderna, Janssen, and AstraZeneca.

What is Now with Novavax?

Novavax shares (NVAX -7.43%) fell on Wednesday, February 23, in no small part due to analysts' rather sharp cut in their target price. By the time the smoke cleared, the biotech stock was down more than 7% on the day. Now the cost of Novavax stock is around $73.50.

Although many countries have already approved Novavax vaccine, the US is still delaying the approval. Novavax stake is on their vaccine to be an alternative for other current vaccines because it’s based on a well-understood protein-based vaccine platform. They are sure that it can prevent COVID-19 better.

However, last autumn FDA declared that Novavax vaccines produced at US plants were not meeting purity standard. It provoked the decrease in NVAX stocks below $140. Now they improved their vaccine to the FDA standards and they’re waiting for its approval.

Analysts’ Predictions

Novavax’s situation will become more apparent after the company’s results of Q4 and 2021 data in general on February 28.

Apparently, most analysts are optimistic about Novavax, and they expect improvement. However, Investing.com forecasts EPS to be -0.36, and cnn.com supposes that it can range from -5.16 to 7.89. Revenue is forecast to be 453.5M.

After the Q3 release, the Novavax stock fluctuated roughly. The company reported a net loss of $322.4 million, or $4.31 per share, for the third quarter of 2021, compared to a net loss of $197.3 million, or $3.21 per share, for the third quarter of 2020. NVAX revenue in the third quarter of 2021 was $178.8 million compared to $157.0 million in 2020.


Many analysts are now quite optimistic about Novavax. In their view, the company will generate large amounts of revenue over the next two years. The problem is that these analysts are still expecting the FDA approval to go into effect relatively soon. Therefore, if there is any failure in this scenario, their predictions may be wrong.  The main pitfall seems to be the slowing down of pandemic, that can lead to irrelevance of this vaccine.


The stock is currently quite cheap. In addition, it is supported by the 200-week MA at 73.90. It’s also in the area, which has been attracting investor demand since 2020. If the company delivers a good report next week, we may see a double bottom and recovery towards $100.

In the longer term, the stock needs to rise above $100 to get to $140. On the contrary, if the price slides below $70, it may be a start of a big selloff.


To sum up, Novavax is at a crossroads, will their statistics help them to improve the situation? Let’s continue to follow the news about this company and we’ll see.



Stocks To Watch For March
Stocks To Watch For March

During his program on CNBC on February 28, Jim Cramer expressed frustration with the impact of earnings reports on market behavior, noting how they often prompt rash decisions by average investors. He criticized the short-term focus and lack of attention to nuance in news coverage of earnings. Cramer cited examples of Home Depot and Lowe's, highlighting how investors reacted hastily to headline news without considering the broader context provided in earnings calls.

How will the reporting season affect US indices?
How will the reporting season affect US indices?

Earnings season is a crucial time for investors and analysts, as it provides insights into how well companies have performed over the past quarter and gives indications of their future earnings. In 2023, expectations for US Q1 earnings were low due to economic challenges and rising interest rates. Surprisingly, many companies beat these low expectations, with 75% of S&P 500 companies surpassing forecasts.

Top Stocks to Invest in 2023
Top Stocks to Invest in 2023

The previous year 2022, was undoubtedly tumultuous for the stock markets, with several stocks plummeting across multiple industries. Analysts have blamed the hard times on inflation, hawkish federal reserve policies, an impending global recession, and the ongoing crisis in Ukraine. This year, however, we're beginning to see some recovery in the stock markets. This article will find a few stocks worth buying this year.

Latest news

USD: Powell Speaks on Cutting Interest Rates
USD: Powell Speaks on Cutting Interest Rates

Jerome H. Powell, the Federal Reserve chair, stated that the central bank can afford to be patient in deciding when to cut interest rates, citing easing inflation and stable economic growth. Powell emphasized the Fed's independence from political influences, particularly relevant as the election season nears. The Fed had raised interest rates to 5.3 ...

WTT: Currency Pairs To Trade In April
WTT: Currency Pairs To Trade In April

Hello again my friends, it’s time for another episode of “What to Trade,” this time, for the month of April. As usual, I present to you some of my most anticipated trade ideas for the month of April, according to my technical analysis style. I therefore encourage you to do your due diligence, as always, and manage your risks appropriately.

Deposit with your local payment systems

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.


A manager will call you shortly.

Change number

Your request is accepted.

A manager will call you shortly.

Next callback request for this phone number
will be available in

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later

Don’t waste your time – keep track of how NFP affects the US dollar and profit!

You are using an older version of your browser.

Update it to the latest version or try another one for a safer, more comfortable and productive trading experience.

Safari Chrome Firefox Opera